Addressing the heart‑disease risk that today’s drugs leave behind
Even with medication, millions remain at risk for cardiovascular events. This innovation points toward a new class of therapies that address the full range of harmful blood lipoproteins—opening more complete and durable protection for patients underserved by today’s standard treatments.